| 货号 | 21511-1mg |
| 描述 | Lixivaptan is a nonpeptide antagonist of vasopressin V2 receptors (Ki = 2.3 nM).1 It is 100-fold selective for V2 over V1a.2 Formulations containing lixivaptan decrease urinary excretion of aquaporin-2 in patients with chronic heart failure and increase serum sodium levels in patients with hyponatremia due to congestive heart failure.3,4 |
| 别名 | VPA-985;WAY-VPA-985; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Matthews, J.M.,Hoekstra, W.J.,Dyatkin, A.B., et al. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg. Med. Chem. Lett. 14(11), 2747-2752 (2004). 2.Izumi, Y.,Miura, K., and Iwao, H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J. Pharmacol. Sci. 124(1), 1-6 (2014). 3.Bowman, B.T., and Rosner, M.H. Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia. Core Evid. 8, 47-56 (2013). 4.Martin, P.-Y.,Abraham, W.T.,Lieming, X., et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. 10(10), 2165-2170 (1999). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥97% |
| 计算分子量 | 473.9 |
| 分子式 | C27H21ClFN3O2 |
| CAS号 | 168079-32-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |